🔬💉 Vaccine Breakthroughs: Shingles, Mpox, Kidney Cancer, RSV and More 🌍💉🧬
In this week’s edition of Vaccine Research Updates, we highlight the cutting-edge innovations advancing global immunization—from streamlined adult vaccines to personalized oncology breakthroughs. These are the stories shaping the future of vaccine science:
💉 GSK’s Shingrix now FDA-approved in a prefilled syringe format—offering over 90 percent efficacy with simplified delivery for adults aged 50+ and immunocompromised individuals 18 and older.
🧒 Sanofi and SK Bioscience launch Phase 1 and 3 trials in China for GBP410, a 21-valent pediatric pneumonia vaccine designed to protect against the broadest range of pneumococcal serotypes.
🌬️ Sanofi acquires Vicebio for $1.6 billion, adding fridge-stable, non-mRNA vaccine candidates for RSV, hMPV, and PIV3. VXB-241 is now in Phase 1 with pivotal data due in 2025.
🧬 GeoVax secures EMA approval to bypass early trials for its Mpox vaccine, GEO-MVA—fast-tracking it to Phase 3 using immuno-bridging. The vaccine will compete with Imvanex amid rising Mpox concerns.
🧠 A personalized neoantigen vaccine shows promise in clear cell renal cell carcinoma, delivering durable T-cell responses and zero recurrence over a 40.2-month median follow-up. Phase 2 trials with Keytruda are underway.
🧪 Scancell’s iSCIB1+ chosen for late-stage melanoma trials after showing a 69 percent response rate when combined with Opdivo and Yervoy. Patient eligibility expands to 80 percent, outperforming historical benchmarks.
🍁 Bavarian Nordic’s Chikungunya vaccine enters Health Canada review, backed by data from over 3,500 participants and a 97.8 percent seroresponse in individuals aged 12 to 64. The single-dose shot has already been approved in the U.S., EU, and UK.
📢 Stay Ahead in Vaccine Research!
✅ Like, share, and subscribe for weekly updates on vaccine innovations and global immunization progress
#VaccineResearch #ShinglesVaccine #ChikungunyaVaccine #MpoxVaccine #NeoantigenTherapy #MelanomaVaccine #RSVVaccine #Sanofi #SKBioscience #GeoVax #BavarianNordic #LucidQuest #LQVentures #ClinicalTrials #InfectiousDiseases #PublicHealth #BiotechInnovation #KidneyCancer #GSK #ImmunizationUpdates #GlobalHealth #HealthcareConsulting